0
Clotting problems and resulting complications are common in COVID-19 patients. Researchers have now shown that a member of the anticoagulant group of drugs not only has a beneficial effect on survival of COVID-19 patients, but also influences the duration of active infection with the SARS-CoV-2 coronavirus.